[An early phase II trial combining cisplatin and carboplatin in advanced non-small cell lung cancer].
We conducted an early phase II trial in advanced non-small cell lung cancer (NSCLC) to evaluate response efficacy of a combination of Cisplatin (CDDP) and Carboplatin (CBDCA). The twenty-six patients in the study had had no previous treatment. They received a sequential administration of 300 mg/m2 CBDCA and 80 mg/m2 CDDP with approximately 3,500 ml of hydration on day 1 every 4 weeks. All patients were evaluable for response and toxicity. Ten (38.5%) of all assessable patients achieved a partial response (95% confidence interval, 19.8-57.2%). Response rates for patients with stage III A, III B and IV- disease were 40.0 (2/5), 70.0 (7/10) and 9.1% (1/11), respectively. Response rates for patients with squamous cell carcinoma, adenocarcinoma and large cell carcinoma were 35.7 (5/14), 45.5 (5/11) and 0.0% (0/1), respectively. The median survival time (MST) of all patients was 11 months. The MST for patients with stage III disease was 14 months; for those with stage IV disease it was 7 months. The MST for responding patients was 15 months and for not responding patients 5 months. Major toxicities were hematologic and gastrointestinal, and the dose-limiting factor was thrombocytopenia. This combination chemotherapy was effective against NSCLC with tolerable toxicities. Further trials are warranted to determine the efficacy of the combination chemotherapy.
Fourth Dept. of Internal Medicine, Nippon Medical School.
A
A
Yoshimura
Y
Y
Yamano
A
A
Gemma
K
K
Yoshimori
K
K
Hayashihara
Y
Y
Taniguchi
K
K
Uematsu
M
M
Shibuya
S
S
Kudoh
H
H
Niitani
D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D005665:Furosemide / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008353:Mannitol / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D008787:Metoclopramide / Q000008:administration & dosage; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced
D008353:Mannitol; D005665:Furosemide; D016190:Carboplatin; D008787:Metoclopramide; D002945:Cisplatin; D008775:Methylprednisolone